NSE filing, NSE: NIDAN. Summary written from the filing by ALFA Finder's alert engine.
Nidan Laboratories And Healthcare Ltd: key numbers
- Share price
- ₹13.00
- Market cap
- ₹18.07 Cr
- Revenue (annual)
- ₹25.54 Cr
- Net profit (annual)
- ₹1.51 Cr
- P/E (TTM)
- 12.0×Sector 51.1×
- Promoter holding
- 57.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nidan Laboratories And Healthcare Ltd
All →Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited conducted its 26th Annual General Meeting on September 28, 2026. Shareholders considered agenda items including financial statement adoption and director re-appointments.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will hold its 26th Annual General Meeting on September 28, 2026. The company has submitted its Annual Report for FY 2025-26.
Nidan Laboratories And Healthcare Annual General Meeting
Nidan Laboratories and Healthcare Limited will convene its 26th Annual General Meeting on September 28, 2026. The board also approved book closure and e-voting schedules.
Nidan Laboratories And Healthcare Board Meeting Date
Nidan Laboratories and Healthcare Limited has scheduled a board meeting for August 20, 2026. The meeting agenda covers general business matters.
Nidan Laboratories And Healthcare Board Meeting Outcome
Nidan Laboratories approved FY26 audited financial results and re-appointed independent directors and statutory auditors. These board decisions ensure operational continuity and regulatory compliance.
Nidan Laboratories And Healthcare Management Change
Nidan Laboratories re-appointed Nilesh Bide and Abhinay Nerurkar as Independent Directors for five-year terms. These appointments ensure continued board stability and regulatory compliance.
- Execution
- 60 months
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.